Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary

Journal of Clinical Pathology

Volumn 63, Issue 11, 2010, Pages 962-966

  Umezu, Tomokazu ^a   Shibata, Kiyosumi ^a   Kajiyama, Hiroaki ^a   Yamamoto, Eiko ^a   Nawa, Akihiro ^a   Kikkawa, Fumitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYPICAN 3; KI 67 ANTIGEN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ABDOMINAL HYSTERECTOMY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; ASCITES FLUID CYTOLOGY; ASCITES FLUID LEVEL; BILATERAL SALPINGOOOPHORECTOMY; CANCER CELL; CANCER PATIENT; CANCER RESISTANCE; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OMENTECTOMY; OVARY CARCINOMA; OVARY CLEAR CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROPERITONEAL LYMPHADENECTOMY; RISK FACTOR; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYPICANS; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78149327583     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.080234     Document Type: Article

References (29)

1. Kikkawa F, Matsuzawa K, Arii Y, et al. Randomized trial of cisplatin and carboplatin versus cisplatin, vinblastine and bleomycin in ovarian cancer. Gynecol Obstet Invest 2000;50:269-74.
2. Brun JL, Feyler A, Chene G, et al. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000;78:21-7.
3. Schiller W, Rilke F, Degna AT. Parvilocular cystomas of the ovary; report of two cases. Obstet Gynecol 1957;10:28-33.
4. Serov SF. [Nomenclature and classification of esophageal tumors]. Vopr Onkol 1973;19:38-42.
5. Behbakht K, Randall TC, Benjamin I, et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998;70:255-8.
6. Crozier MA, Copeland LJ, Silva EG, et al. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol 1989;35:199-203.
7. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage iii disease. Gynecol Oncol 1996;60:412-17.
8. Jenison EL, Montag AG, Griffiths CT, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989;32:65-71.
9. Kennedy AW, Biscotti CV, Hart WR, et al. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989;32:342-9.
10. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage clear-cell epithelial ovarian cancer: the hellenic cooperative oncology group experience. Gynecol Oncol 2006;102:285-91.
11. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-9.
12. Itamochi H, Kigawa J, Sugiyama T, et al. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002;100:281-7.
13. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008;99:653-8.
14. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001;108:497-501.
15. Hagihara K, Watanabe K, Chun J, et al. Glypican-4 is an fgf2-binding heparan sulfate proteoglycan expressed in neural precursor cells. Dev Dyn 2000; 219:353-67.
16. Ohkawara B, Yamamoto TS, Tada M, et al. Role of glypican 4 in the regulation of convergent extension movements during gastrulation in xenopus laevis. Development 2003;130:2129-38.
17. Song HH, Shi W, Filmus J. Oci-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem 1997; 272:7574-7. (Pubitemid 27137302)
18. Tsuda M, Kamimura K, Nakato H, et al. The cell-surface proteoglycan dally regulates wingless signalling in drosophila. Nature 1999;400:276-80.
19. Desbordes SC, Sanson B. The glypican dally-like is required for hedgehog signalling in the embryonic epidermis of drosophila. Development 2003;130:6245-55.
20. Toretsky JA, Zitomersky NL, Eskenazi AE, et al. Glypican-3 expression in wilms tumor and hepatoblastoma. J Pediatr Hematol Oncol 2001;23:496-9.
21. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18:1591-8.
22. Maeda D, Ota S, Takazawa Y, et al. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol 2009;22:824-32.
23. Stadlmann S, Gueth U, Baumhoer D, et al. Glypican-3 expression in primary and recurrent ovarian carcinomas. Int J Gynecol Pathol 2007;26:341-4.
24. Zynger DL, Everton MJ, Dimov ND, et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol 2008;130:224-30.
25. Umezu T, Shibata K, Shimaoka M, et al. Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo. Cancer Sci 2010;101:143-8.
26. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in gpc3, a glypican gene, cause the simpson-golabi-behmel overgrowth syndrome. Nat Genet 1996;12:241-7.
27. Neri G, Gurrieri F, Zanni G, et al. Clinical and molecular aspects of the simpsongolabi- behmel syndrome. Am J Med Genet 1998;79:279-83.
28. Cano-Gauci DF, Song HH, Yang H, et al. Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of simpson-golabibehmel syndrome. J Cell Biol 1999;146:255-64.
29. Chiao E, Fisher P, Crisponi L, et al. Overgrowth of a mouse model of the simpson-golabi-behmel syndrome is independent of igf signaling. Dev Biol 2002;243:185-206.